ERBB2 and neoplasm: Additionally, the TP53-mutated group had a higher incidence of HR-negative tumor (64.7% vs. 35.9%, p < 0.001) and a greater frequency of HER2-positive tumors (44.2% vs. 26.8%, p < 0.001).